Abstract:The cat eye syndrome chromosome region candidate 2 (CECR2) protein is an epigenetic regulator involved in chromatin remodeling and transcriptional control. The CECR2 bromodomain (CECR2-BRD) plays a pivotal role in directing the activity of CECR2 through its capacity to recognize and bind acetylated lysine residues on histone proteins. This study elucidates the binding specificity and structural mechanisms of CECR2-BRD interactions with both histone and non-histone ligands, employing techniques such as isothermal titration calorimetry (ITC), nuclear magnetic resonance (NMR) spectroscopy, and a high-throughput peptide assay. The CECR2-BRD selectively binds acetylated histone H3 and H4 ligands, exhibiting a preference for multi-acetylated over mono-acetylated targets. The highest affinity was observed for tetra-acetylated histone H4. Neighboring post-translational modifications, including methylation and phosphorylation, modulate acetyllysine recognition, with significant effects observed for histone H3 ligands. Additionally, this study explored the interaction of the CECR2-BRD with the acetylated RelA subunit of NF-κB, a pivotal transcription factor in inflammatory signaling. Dysregulated NF-kappaB signaling is implicated in numerous pathologies, including cancer progression, with acetylation of RelA at lysine 310 (K310ac) being critical for its transcriptional activity. Recent evidence linking the CECR2-BRD to RelA suggests it plays a role in inflammatory and metastatic pathways, underscoring the need to understand the molecular basis of this interaction. We found the CECR2-BRD binds to acetylated RelA with micromolar affinity, and uses a distinctive binding mode to recognize this non-histone ligand. These results provide new insight on the role of CECR2 in regulating NF-κB-mediated inflammatory pathways. Functional mutagenesis of critical residues, such as Asn514 and Asp464, highlight their roles in ligand specificity and binding dynamics. Notably, the CECR2-BRD remained monomeric in solution and exhibited differential conformational responses upon ligand binding, suggesting adaptive recognition mechanisms. Furthermore, the CECR2-BRD exclusively interacts with nucleosome substrates containing multi-acetylated histones, emphasizing its role in transcriptional activation within euchromatic regions. These findings position the CECR2-BRD as a key chromatin reader and a promising therapeutic target for modulating transcriptional and inflammatory processes, particularly through the development of selective bromodomain inhibitors.

Ceap/BLOS2 interacts with BRD7 and selectively inhibits its transcription-suppressing effect on cellular proliferation-associated genes.

Tumor suppressor bromodomain-containing protein 7 cooperates with Smads to promote transforming growth factor-β responses

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation Via Distinct Structural Degrons.

BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer

The CECR2 bromodomain displays distinct binding modes to select for acetylated histone proteins versus non-histone ligands.

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

CEBPA Restrains the Malignant Progression of Breast Cancer by Prompting the Transcription of SOCS2

Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors

BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10

C/EBPβ Is a Transcriptional Regulator of Wee1 at the G2/M Phase of the Cell Cycle

BRD2 Interconnects with BRD3 to Facilitate Pol II Transcription Initiation and Elongation to Prime Promoters for Cell Differentiation.

BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53

CEBPA facilitates LOXL2 and LOXL3 transcription to promote BCL-2 stability and thus enhances the growth and metastasis of lung carcinoma cells in vitro

BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression

BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer

Cebpd Suppresses Prolactin Expression and Prolactinoma Cell Proliferation

RNA-binding Protein CELF6 is Cell Cycle Regulated and Controls Cancer Cell Proliferation by Stabilizing P21

Discovery of Novel CBP Bromodomain Inhibitors Through TR-FRET-based High-Throughput Screening

Brd4 binds to active enhancers to control cell identity gene induction in adipogenesis and myogenesis

Interaction and Functional Research of BRD7 and Adaptor-Related Protein Complex 3δ Protein